Evidence map›Paper›PMID 41510204›Full record

ArticleJAC-antimicrobial resistance2026

An improved algorithm to screen for carbapenemase production in

Justin A Ellem, Mitchell J Brown, Indy Sandaradura, Brian P McSharry, Thiru Vanniasinkam

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JAC-antimicrobial resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Metallo-β-lactamase-producingFrontiers in microbiology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Justin A EllemCentre for Infectious Diseases and Microbiology Laboratory Services, NSW Health Pathology-ICPMR, Westmead Hospital, Sydney, Australia.
Mitchell J BrownCentre for Infectious Diseases and Microbiology Laboratory Services, NSW Health Pathology-ICPMR, Westmead Hospital, Sydney, Australia.
Indy SandaraduraCentre for Infectious Diseases and Microbiology Laboratory Services, NSW Health Pathology-ICPMR, Westmead Hospital, Sydney, Australia.ORCID https://orcid.org/0000-0002-9457-8262
Brian P McSharrySchool of Dentistry and Medical Sciences, Faculty of Science and Health, Charles Sturt University, Wagga Wagga, Australia.
Thiru VanniasinkamSchool of Dentistry and Medical Sciences, Faculty of Science and Health, Charles Sturt University, Wagga Wagga, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: One of the biggest challenges for healthcare providers is the difficulty with screening for carbapenemase-producing, carbapenem-resistant Methods: Antibiograms of a reference set of Results: The CP-CRPa screening algorithm developed here uses meropenem, ceftazidime and tobramycin. Carbapenem resistance was identified in 85 (5.7%) isolates, of which 26 (1.8%) were confirmed as CP-CRPa. Conclusions: We present an antimicrobial susceptibility testing-based screening algorithm that uses meropenem, ceftazidime, and tobramycin to screen for CP-CRPa. When appropriate screening criteria are utilized, confirmatory testing can be significantly reduced, resulting in substantial time and resource savings, without compromising sensitivity, particularly in settings with varying carbapenemase epidemiology.

Identifiers

PMID41510204
PMCPMC12776346

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.